Article Text

other Versions

PDF
Extended report
Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis
  1. Gulsen Ozen1,2,
  2. Sofia Pedro3,
  3. Marie E Holmqvist4,
  4. Michael Avery5,
  5. Frederick Wolfe3,
  6. Kaleb Michaud1,3
  1. 1University of Nebraska Medical Center, Omaha, Nebraska, USA
  2. 2Faculty of Medicine, Marmara University, Istanbul, Turkey
  3. 3National Data Bank for Rheumatic Diseases, Wichita, Kansas, USA
  4. 4Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
  5. 5Regional Health, Rapid City, South Dakota, USA
  1. Correspondence to Dr Kaleb Michaud, 986270 Nebraska Medical Center, Omaha, NE 68198, USA; kmichaud{at}unmc.edu

Abstract

Objective To investigate the rate of incident diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) and the impact of disease-modifying antirheumatic drug (DMARD) and statin treatments.

Methods We studied patients with RA and ≥1 year participation in the National Data Bank for Rheumatic Diseases without baseline DM from 2000 through 2014. DM was determined by self-report or initiating DM medication. DMARDs were categorised into four mutually exclusive groups: (1) methotrexate monotherapy (reference); (2) any abatacept with or without synthetic DMARDs (3) any other DMARDs with methotrexate; (4) all other DMARDs without methotrexate; along with separate statin, glucocorticoid and hydroxychloroquine (yes/no) variables. Time-varying Cox proportional hazard models were used to adjust for age, sex, socioeconomic status, comorbidities, body mass index and RA severity measures.

Results During a median (IQR) 4.6 (2.5–8.8) years of follow-up in 13 669 patients with RA, 1139 incident DM cases were observed. The standardised incidence ratio (95% CI) of DM in patients with RA (1.37, (1.29 to 1.45)) was increased compared with US adult population. Adjusted HR (95% CI) for DM were 0.67 (0.57 to 0.80) for hydroxychloroquine, 0.52 (0.31 to 0.89) for abatacept (compared with methotrexate monotherapy), 1.31 (1.15 to 1.49) for glucocorticoids and 1.56 (1.36 to 1.78) for statins. Other synthetic/biological DMARDs were not associated with any risk change. Concomitant use of glucocorticoids did not alter DM risk reduction with hydroxychloroquine (HR 0.69 (0.51 to 0.93)).

Conclusions In RA, incidence of DM is increased. Hydroxychloroquine and abatacept were associated with decreased risk of DM, and glucocorticoids and statins with increased risk.

  • Rheumatoid Arthritis
  • DMARDs (biologic)
  • DMARDs (synthetic)
  • Outcomes research

Statistics from Altmetric.com

Footnotes

  • Handling editor Tore K Kvien

  • The results have been presented before in abstract form in American College of Rheumatology Annual Meeting 2016.

  • Contributors All authors participated in the conception and design of the study. GO, SP and KM analysed and drafted the manuscript. All authors contributed to the interpretation of the results and reviewed the manuscript.

  • Funding KM was supported by the Rheumatology Research Foundation Investigator Award.

  • Competing interests None declared.

  • Ethics approval This study was conducted with the approval of the Via Christi Regional Medical Center Institutional Review Board, and patients provided informed written consent prior to study enrolment.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.